Article
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Science signaling - 11 Nov 2014
Belmont Peter J, Jiang Ping, McKee Trevor D, Xie Tao, Isaacson Jason, Baryla Nicole E, Roper Jatin, Sinnamon Mark J, Lee Nathan V, Kan Julie L C, Guicherit Oivin, Wouters Bradly G, O'Brien Catherine A, Shields David, Olson Peter, VanArsdale Todd, Weinrich Scott L, Rejto Paul, Christensen James G, Fantin Valeria R, Hung Kenneth E, Martin Eric S
Abstract excerpt
Targeted blockade of aberrantly activated signaling pathways is an attractive therapeutic strategy for solid tumors, but drug resistance is common. KRAS is a frequently mutated gene in human cancer but remains a challenging clinical target. Inhibitors against KRAS signaling mediators, namely, PI3K (phosphatidylinositol 3-kinase) and mTOR (mechanistic target of rapamycin), have limited clinical efficacy as single...
Topics
- Animals
- Cell Line, Tumor
- Cell Proliferation
- Cell Separation
- Cell Survival
- Colorectal Neoplasms
- Disease Models, Animal
- Drug Resistance, Neoplasm